The Pharmaceutical Journal
Vol 272 No 7283 p79
24 January 2004

This article
Reprint
Photocopy

News summary

Related websites
New England Journal of Medicine abstract (more)

No extra benefit from abciximab

Patients who undergo elective percutaneous coronary intervention after pretreatment with clopidogrel (Plavix) do not gain additional benefit from treatment with abciximab (ReoPro), data from a European trial suggests (New England Journal of Medicine 2004;350:232).